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K e y  M e s s a g e s 
1. This study investigated the geographical 
distribution and growth properties of avian 
influenza A (H5N1) isolates with mutations 
that confer resistance to amantadine and 
rimantadine. It also explored whether naturally 
occurring mutations associated with resistance 
to oseltamivir are present at a low frequency in 
H5N1 isolates and if so, whether these quasi-
species may be the source of the emergence of 
oseltamivir-resistant strains following exposure 
to this drug.  
2. Naturally occurring avian H5N1 virus mutants 
H5N1 virus resistant to antiviral drug
Avian influenza A (H5N1) virus is common in poultry 
and has caused sporadic human infections since 
2003. Antiviral drugs are essential to contain and 
delay the spread of the virus. Nonetheless, resistance 
to the M2 ion channel blockers, amantadine and 
rimantadine, and the neuraminidase inhibitor—
oseltamivir—have been detected in H5N1 virus. 
 Human infections with H5N1 virus were first 
documented in Hong Kong in 1997 and then in 
China in 2003. More than 500 human infections have 
been identified in 15 countries; over 50% of cases are 
fatal.1
 Currently available anti-influenza drugs 
(adamantanes, amantadine, and rimantadine) 
block the ion channel formed by the M2 protein of 
the influenza virus, as well as the neuraminidase 
inhibitors—oseltamivir and zanamivir.2 
 Resistance to amantadine and rimantadine has 
been detected in human influenza viruses, including 
the pandemic (H1N1) 2009 virus,3 and in avian 
H5N1 viruses isolated in Vietnam and Thailand 
in 2004 and 2005.4 Stockpiling of neuraminidase 
inhibitors, in particular oseltamivir, is recommended 
by the World Health Organization in response to a 
potential pandemic. The efficacy of oseltamivir in 
the treatment of H5N1 infection is not clear, and 
resistant variants have been identified in H5N1 
human cases treated with oseltamivir.1 Emergence 
of resistance to oseltamivir in seasonal H1N1 virus 
since 2007 suggests that the resistance mutation—
His274Tyr—may occur naturally.5 This study aimed 
to investigate whether resistance to amantadine 
is also prevalent in H5N1 viruses, and whether 
mutations associated with oseltamivir resistance 
occur in avian H5N1 viruses. 
 Resistance to amantadine and rimantadine is 
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mainly found in H5N1 viruses circulating in Vietnam 
and Thailand during 2004 and 2005 (data not shown). 
The dual Leu26Ile and Ser31Asn mutations in the 
M2 gene are responsible for this resistance. In vitro, 
the dual Leu26Ile and Ser31Asn mutations confer a 
growth advantage to the H5N1 virus, especially at 
40ºC. This suggests a possible mechanism for the 
expansion of mutant viruses in poultry that have 
a higher body temperature than humans (Fig). 
Resistance to adamantanes is much less prevalent in 
H5N1 viruses circulating in Indonesia, the Middle 
East, and China. This suggests that these drugs may 
still have prophylactic and therapeutic value for the 
H5N1 virus. 
 Resistance to the neuraminidase inhibitor—
oseltamivir—has been found in H5N1 viruses. It 
is not clear whether the mutation—His274Tyr—
originated in patients during treatment or whether 
it is derived from an avian source. In 2002, a H5N1 
isolate was found to contain the His274Tyr mutation 
and was resistant to oseltamivir. His274Tyr quasi-
species in H5N1 virus isolates were examined to 
investigate whether the His274Tyr mutant virus 
might naturally occur at low levels mixed with wild 
type virus in H5N1 poultry infections (data not 
shown). The His274Tyr quasi-species were more 
frequently found in isolates from infected chickens 
than from other ducks and geese, but no geographical 
difference was noted. His274Tyr mutant H5N1 
viruses exhibited host specificity. A distinctive 
interaction between the HA and the NA proteins 
in some H5N1 isolates may also result in reduced 
susceptibility to oseltamivir. The mechanism for 
the emergence of the dominant His274Tyr in H1N1 
virus was investigated to understand the fitness of 
the NA gene in N1 subtype viruses. 
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resistant to the main types of antiviral drugs were 
noted.
3. The fitness of these mutants in avian and 
mammalian hosts needs further investigation.
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 Although vaccination is a principal defence 
against influenza, rapid vaccine development during 
a pandemic is challenging. Antiviral drugs play an 
essential role in the control of an outbreak, delaying 
virus spread, as well as preventing and treating 
disease. A clear profile of H5N1 resistance to anti-
influenza drugs is not available, as studies are still in 
the animal phase.
 Although amantadine-resistant viruses 
have been found in Asia, their distribution was 
geographically and temporally confined to Thailand, 
Vietnam, and Cambodia; most isolates from other 
places are sensitive to amantadine, as have been 
most avian H5N1 viruses detected since 2006. This 
apparent geographical disparity in the susceptibility 
of H5N1 isolates to amantadine is unknown. The 
distinct and conserved pattern of the paired Leu26Ile 
and Ser31Asn mutations suggests that the Thai, 
Vietnamese, and Cambodian viruses originated from 
a single virus introduced into or generated within 
the region. Dual Leu26Ile and Ser31Asn mutations 
are rare among other influenza A viruses. The high 
incidence of 26Ile and its exclusive association with 
31Asn in H5N1 isolates suggest that viruses carrying 
the dual mutation were stably selected; no single 
26Ile variants were detected. 
 Neuraminidase inhibitors are the first-line 
antivirals for a pandemic. Resistance to oseltamivir 
has been reported in human H5N1 isolates. 
Oseltamivir-resistant strains bearing the His274Tyr 
mutation are present at low levels within some H5N1 
virus populations. Isolation of one resistant mutant 
strain from an infected chicken suggests that such 
naturally occurring mutants may become the main 
population if they gain growth fitness in the host. 
This assertion is supported by the spread of a seasonal 
H1N1 virus carrying the His274Tyr oseltamivir-
resistance mutation since 2007. Naturally occurring 
His274Tyr mutations in the 2009 H1N1 virus were 
also characterised. It is important to closely survey 
genetic mutations associated with resistance to 
neuraminidase inhibitors in influenza A viruses, and 
to study the replication fitness of resistant variants. 
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FIG.  Growth properties of amantadine-resistant variant in MDCK cells H5N1 virus 
strain A/Vietnam/1194/04 (26Ile & 31Asn in M2 gene and resistant to amantadine) 
and a recombinant version of the same virus (26Leu & 31Ser in M2 gene and 
susceptible to amantadine) for growth kinetics in MDCK cells cultured at (a) 37ºC 
and (b) 40ºC
8
7
6
5
4
3
2
1
0
Time (hours) post infection
M
ea
n 
Lo
g 1
0T
C
ID
50
12 24 48 60
26Ile & 31Asn
26Leu & 31Ser
6
5
4
3
2
1
0
Time (hours) post infection
M
ea
n 
Lo
g 1
0T
C
ID
50
12 24 48 60
26Ile & 31Asn
26Leu & 31Ser
(a)
(b)
